Are heart failure observational studies still useful? ‘No need to argue’*

Piepoli MF Abreu A Albus C , et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol 2020; 27: 181–205. 2019/12/12. DOI: 10.1177/2047487319893035.

Ziaeian B Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016; 13: 368–378. 2016/03/03. DOI: 10.1038/nrcardio.2016.25.

Bowman L Baras A Bombien R , et al. Understanding the use of observational and randomized data in cardiovascular medicine. Eur Heart J. Epub ahead of print 4 February 2020. DOI: 10.1093/eurheartj/ehaa020.

Frieden TR. Evidence for health decision making – beyond randomized, controlled trials. N Engl J Med 2017; 377: 465–475. DOI: 10.1056/NEJMra1614394.

Salzano A Israr MZ Garcia DF , et al. Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure. Eur J Prev Cardiol. Epub ahead of print 25 March 2020. DOI: 10.1177/2047487320912375.

Salzano A, D'Assante R, Stagnaro FM, et al. Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre. Eur J Heart Fail. Epub ahead of print 28 May 2020. DOI: 10.1002/ejhf.1911.

Crespo-Leiro MG Anker SD Maggioni AP , et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): One-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016; 18: 613–625. DOI: 10.1002/ejhf.566.

Lund LH Carrero JJ Farahmand B , et al. Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study. Eur J Heart Fail 2017; 19: 1107–1116. 2017/02/23. DOI: 10.1002/ejhf.762.

Littlejohns TJ Sudlow C Allen NE , et al. UK Biobank: opportunities for cardiovascular research. Eur Heart J 2019; 40: 1158–1166. DOI: 10.1093/eurheartj/ehx254.

Santema BT Ouwerkerk W Tromp J , et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 2019; 394: 1254–1263. 2019/08/22. DOI: 10.1016/S0140-6736(19)31792-1.

Yazaki Y Salzano A Nelson CP , et al. Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. Eur J Heart Fail 2019; 21: 1291–1294. 2019/07/28. DOI: 10.1002/ejhf.1550.

Salzano A Israr MZ Yazaki Y , et al. Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. Eur J Prev Cardiol. Epub ahead of print 14 August 2019. DOI: 10.1177/2047487319870355.

Bossone E Arcopinto M Iacoviello M , et al. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry. Intern Emerg Med 2018; 13: 661–671. 2018/04/04. DOI: 10.1007/s11739-018-1844-8.

Göbel S Prochaska Jr HT Paniva-Noeva S-O , et al. Rationale, design and baseline characteristics of the MyoVasc Study – a prospective cohort study investigating development and progression of heart failure Eur J Prev Cardiol. Epub ahead of print 14 May 2020. DOI: 10.1177/2047487320926438.

Morbach C Gelbrich G Tiffe T , et al. Prevalence and determinants of the precursor stages of heart failure: results from the population-based STAAB cohort study. Eur J Prev Cardiol. Epub ahead of print 6 May 2020. DOI: 10.1177/2047487320922636.